Back to Search Start Over

Engineered T Cell Therapy for Cancer in the Clinic.

Authors :
Zhao L
Cao YJ
Source :
Frontiers in immunology [Front Immunol] 2019 Oct 11; Vol. 10, pp. 2250. Date of Electronic Publication: 2019 Oct 11 (Print Publication: 2019).
Publication Year :
2019

Abstract

T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell and TCR-T cell therapies have produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. This article summarizes the current applications of CAR-T cell and TCR-T cell therapies in clinical trials worldwide. It is predicted that genetically engineered T cell immunotherapies will become safe, well-tolerated, and effective therapeutics and bring hope to cancer patients.<br /> (Copyright © 2019 Zhao and Cao.)

Details

Language :
English
ISSN :
1664-3224
Volume :
10
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
31681259
Full Text :
https://doi.org/10.3389/fimmu.2019.02250